Epiconcept, Paris, France.
National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
Influenza Other Respir Viruses. 2024 Feb;18(2):e13255. doi: 10.1111/irv.13255.
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
我们开展了一项多中心医院基于病例对照的研究，以测量 2022/2023 流感季节期间欧洲严重急性呼吸道感染（SARI）成年患者中 PCR 确诊流感的疫苗效力（VE）。在 5547 例≥18 岁的 SARI 患者中，有 2963 例（53%）接种了流感疫苗。总体上，流感 A（H1N1）pdm09 的 VE 为 11%（95%CI：-23-36）；A（H3N2）为 20%（95%CI：-4-39），B 为 56%（95%CI：22-75）。在 2022/2023 季节，流感 B 导致住院的 VE ＞55%，而流感 A 亚型的 VE≤20%。虽然流感疫苗接种应该是未来季节的优先事项，但需要改进针对流感的疫苗。
